Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

News

ESMO 2021: GEMSTONE-301 Trial of Novel PD-L1 Inhibitor in Unresectable Stage III NSCLC

Medical Literature

Can Neuronal Autoantibodies Influence Cognitive Impairment in Patients With Lung Cancer?

News

CheckMate 9LA: Dual Immunotherapy Plus Chemotherapy for Patients With NSCLC and Brain Metastases

News

ESMO 2021: Novel Antibody-Drug Conjugate Under Study in Advanced Lung Cancer

News

IASLC 2021: Antibody Response to SARS–CoV-2 Vaccination in Patients With Lung Cancer

News

FDA Approves Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Medical Literature

Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel in Advanced Lung Cancer

Robin Cornelissen, MD, PhD, on ZENITH20-4: Use of Poziotinib Under Study in HER2 Exon 20–Mutated NSCLC

Martin Reck, MD, PhD, on Monotherapy vs Combination Treatment for High PD-L1–Expressing NSCLC: Expert Perspective

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

View More

More

News

Preliminary Results With Novel EGFR Inhibitor for EGFR-Mutated Lung Cancer

IASLC Consensus Statement on Liquid Biopsy for Patients With Advanced NSCLC

IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC

Does the Use of Metformin Improve Outcomes in Patients With Non–Small Cell Lung Cancer?

IASLC 2021: CheckMate 907 on De Novo Administration of Nivolumab in Advanced NSCLC

Atezolizumab Receives Priority Review From the FDA in Early NSCLC

IASLC 2021: Disparities in Lung Cancer Care

ESMO 2021: Patterns of Relapse From IMpower010 of Atezolizumab Versus Best Supportive Care in NSCLC

View More

Advertisement

Published

Medical Literature

Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?

Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study

Brigatinib in Patients With Crizotinib-Refractory ALK-Positive NSCLC

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

View More

Ongoing

CE Activities

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Novel and Emerging Therapeutic Strategies in the Management of Non–Small Cell Lung Cancer

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

Consensus or Controversy? Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum

View More

Available

Clinical Trials

City of Hope Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.